Equities Analysts Offer Predictions for ANRO FY2024 Earnings

Alto Neuroscience, Inc. (NYSE:ANRO) – Stock analysts at Wedbush lowered their FY2024 EPS estimates for Alto Neuroscience in a research report issued on Wednesday, November 13th. Wedbush analyst L. Chico now expects that the company will earn ($2.60) per share for the year, down from their previous estimate of ($2.58). Wedbush currently has a “Neutral” rating and a $4.00 price objective on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.63) per share. Wedbush also issued estimates for Alto Neuroscience’s Q4 2024 earnings at ($0.66) EPS, FY2026 earnings at ($2.25) EPS and FY2027 earnings at ($2.32) EPS.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.05.

A number of other equities research analysts have also recently commented on ANRO. Stifel Nicolaus dropped their target price on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday. Robert W. Baird dropped their price objective on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Rodman & Renshaw downgraded Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 23rd. RODMAN&RENSHAW cut shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Finally, William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Alto Neuroscience Stock Performance

Alto Neuroscience stock opened at $4.52 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 19.85 and a current ratio of 13.10. The stock’s 50 day simple moving average is $9.86 and its two-hundred day simple moving average is $11.41. Alto Neuroscience has a 12 month low of $3.61 and a 12 month high of $24.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its position in Alto Neuroscience by 619.2% in the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after purchasing an additional 3,715 shares during the period. Rhumbline Advisers acquired a new stake in shares of Alto Neuroscience in the second quarter valued at $113,000. Jane Street Group LLC purchased a new stake in shares of Alto Neuroscience in the 3rd quarter valued at $124,000. Federated Hermes Inc. lifted its stake in Alto Neuroscience by 33.3% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $128,000 after acquiring an additional 3,000 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new position in Alto Neuroscience in the 3rd quarter valued at about $146,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.